Výsledky vyhledávání - "Valerie Israel"

Chemotherapy-Induced Activation of Hemostasis: Effect of a Low Molecular Weight Heparin (Dalteparin Sodium) on Plasma Markers of Hemostatic Activation

Autor: Ilene C. Weitz, Valerie Israel, Leanne Rochanda, Cary A. Presant, James Waisman, Howard A. Liebman

Publikováno v: Thrombosis and Haemostasis. 88:213-220

SummaryTo evaluate the effect of standard chemotherapeutic regimens on the hemostatic profile of patients with breast and lung carcinoma; and to evaluate the effect of a single dose of a low molecular weight (LMW) heparin, dalteparin sodium, administ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f2f424a4f5d30cf0a6c67aa7cdd70a1a
https://doi.org/10.1055/s-0037-1613190

Zobrazit plný text záznamu

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial

Autor: Primo N. Lara, Derick H Lau, Jeff Longmate, Paul Frankel, Heinz-Josef Lenz, Edith A. Perez, Regina F Gandour-Edwards, James Raschko, David R. Gandara, James H. Doroshow, Paul H. Gumerlock, Philip C. Mack, Martin J. Edelman, Valerie Israel

Publikováno v: Cancer Chemotherapy and Pharmacology. 48:22-28

Purpose: Although cisplatin is an important agent in non-small-cell lung cancer (NSCLC), de novo resistance is common and acquired resistance emerges rapidly during therapy. Proposed mediators of platinum resistance include the protein kinase C (PKC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e111e9a8784fd66ee2f8f27183dd6c
https://doi.org/10.1007/s002800100293

Zobrazit plný text záznamu

Twice-Weekly Paclitaxel and Weekly Carboplatin With Concurrent Thoracic Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non–Small-Cell Lung Cancer: A California Cancer Consortium Phase II Trial

Autor: Derick H Lau, David R. Gandara, Bryan R. Leigh, Primo N. Lara, Richard B. Wilder, Martin J. Edelman, James Doroshow, Robert J. Morgan, J. Ryu, Valerie Israel

Publikováno v: Journal of Clinical Oncology. 19:442-447

PURPOSE: Recent studies have suggested the superiority of concurrent chemoradiotherapy and the efficacy of paclitaxel/carboplatin in advanced non–small-cell lung cancer (NSCLC). In view of those results, we sought to examine the safety and efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65df349033df4ed8180a55b39e90d74c
https://doi.org/10.1200/jco.2001.19.2.442

Zobrazit plný text záznamu

Phase 2 study of cryptophycin 52 ( LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer

Autor: Jennifer DeSanto, Petr F. Hausner, David R. Gandara, Martin J. Edelman, Donald Thornton, Valerie Israel, L. Austin Doyle

Publikováno v: Lung Cancer. 39:197-199

Background: Cryptophycin 52 is a novel antitubulin drug with in vitro and in vivo activity in non-small cell lung cancer. Based upon promising Phase 1 data, a multicenter trial was performed to evaluate the drug in previously treated non-small cell l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9637b61eb81f40ad926fd931fc50131
https://doi.org/10.1016/s0169-5002(02)00511-1

Zobrazit plný text záznamu

Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718

Autor: David R. Gandara, John Crowley, Karen Kelly, Richard Grapski, Kari Chansky, Valerie Israel, Paul J. Hesketh, C. Harris Spiridonidis, Tarek Mekhail, Glenn Mills

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2(5)

Background This phase II study (S9718) evaluated the antineoplastic activity and tolerability of the combination of gemcitabine and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ES-SCLC). Methods Chemonaive p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258aabe97e4a1cdf79953b401fb505e8
https://pubmed.ncbi.nlm.nih.gov/17473660

Zobrazit plný text záznamu

Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial

Autor: Regina F Gandour-Edwards, Kathy S. Albain, Gayatri P. Reddy, David R. Gandara, Primo N. Lara, Paul H. Gumerlock, Valerie Israel, Lisa Y. Law, Jeff Longmate, Derick H Lau, James H. Doroshow, Paul Frankel, Philip C. Mack, Martin J. Edelman

Publikováno v: Clinical lung cancer. 6(2)

A phase II trial was designed to evaluate the efficacy and toxicity of gemcitabine in patients with non-small-cell lung cancer (NSCLC) previously treated with platinum-containing regimens and prospectively categorized for platinum response status. Tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd7435be850e592ffc83fb12ca7764ef
https://pubmed.ncbi.nlm.nih.gov/15476595

Zobrazit plný text záznamu

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

Autor: Terry Snyder, Scott T. Tagawa, Susan Jeffers, Valerie Israel, Derek Raghavan

Publikováno v: Investigational new drugs. 22(3)

Introduction: The poor prognosis of non small cell lung cancer (NSCLC), as well as the significant toxicity from many conventional cytotoxic regimens warrants the investigation of combinations of new active agents for treatment. This is a phase I–I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4feb6a78f329e2dbd9646fb3b892d0
https://pubmed.ncbi.nlm.nih.gov/15122076

Zobrazit plný text záznamu

Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial

Autor: Paula K. Locker, Gary Elfring, Mark A. Socinski, Alan B. Sandler, Langdon L. Miller, Nicoletta Pirotta, Ronald B. Natale, Cristy K. Hanover, Valerie Israel

Publikováno v: Clinical lung cancer. 2

The objectives of this phase I/II trial were to determine the maximum tolerated dose, toxicities, and the dose suitable for phase II/III trials of irinotecan (CPT-11) combined with paclitaxel and carboplatin in patients with advanced non–small-cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b243b3435012bbb63983485dc679e01
https://pubmed.ncbi.nlm.nih.gov/14725727

Zobrazit plný text záznamu

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

Autor: Antoinette J. Wozniak, Patra K. Grevstad, Scott D. Ramsey, Paul A. Bunn, Valerie Israel, Karen Kelly, Robert B. Livingston, Dennis F. Moore, John Crowley, Geoffrey R. Weiss, Carol M. Moinpour, Cary A. Presant, David R. Gandara

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(13)

PURPOSE: This randomized trial was designed to determine whether paclitaxel plus carboplatin (PC) offered a survival advantage over vinorelbine plus cisplatin (VC) for patients with advanced non–small-cell lung cancer. Secondary objectives were to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8af21a6913f6a1e803c9e0f2074dca2
https://pubmed.ncbi.nlm.nih.gov/11432888

Zobrazit plný text záznamu

Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer

Autor: Paula K. Locker, Cristy K. Hanover, Valerie Israel, Nicoletta Pirotta, Ronald B. Natale, Mark A. Socinski, Alan B. Sandler, Langdon L. Miller, Gary Elfring

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(4)

PURPOSE: To determine the maximum-tolerated dose, toxicities, and dose suitable for phase II/III trials of irinotecan (CPT-11) combined with paclitaxel and carboplatin in patients with advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71b1c74d5f974ea65197b75d831485f2
https://pubmed.ncbi.nlm.nih.gov/11181672

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání